On March 7, 2019, the U.S. Food and Drug Administration (FDA) approved a supplemental application for Opdivo (nivolumab). This approval specifically pertains to the drug's efficacy profile, as indicated by the application's classification. The application was sponsored by Bristol Myers Squibb.
What this means
This supplemental approval for Opdivo (nivolumab), granted by the FDA on March 7, 2019, signifies an expansion of the drug's recognized efficacy. Supplemental applications for efficacy typically involve new data supporting a broader use of an already approved medication. This could include a new indication, an expanded patient population, or a change in dosing regimen that demonstrates improved outcomes. While the specific details of this expanded efficacy are not provided in this record, such approvals are important milestones that allow healthcare providers to consider nivolumab for additional therapeutic applications. For clinicians, this means an updated understanding of Opdivo's potential utility in patient treatment. Researchers will be interested in the underlying data that supported this efficacy expansion, and patient advocates will note the potential for new treatment options involving nivolumab.
Source
The information regarding this supplemental efficacy approval was sourced from the official FDA database. The approval for BLA 125554 S-42, pertaining to Opdivo (nivolumab), was documented on March 7, 2019, on the accessdata.fda.gov website.